XML 135 R42.htm IDEA: XBRL DOCUMENT v3.25.1
BUSINESS COMBINATION (Details Narrative) - USD ($)
12 Months Ended
Feb. 14, 2024
Dec. 31, 2024
Dec. 31, 2023
Common stock, shares outstanding 164,614,418 177,991,365 119,999,989
Merger transaction costs $ 7,728,681 $ 7,499,353
Transaction costs charged to equity 229,328    
New issuance value $ 3,613,000 $ 3,613,000  
Earnout Shares [Member]      
Earnout shares issuable 24,500,000    
Tevogen Bio [Member]      
Ownership percentage   91.00%